Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and sluggish change, are hindering access.

A new study reveals how an IL-21 mimic harnesses CD4 T cells to turn transient KRAS inhibitor responses into durable pancreatic cancer remissions in mice.

Rates of colon cancer in people younger than 55 have doubled in the last 25 years. Academic researchers are working to solve the mystery and improve outcomes.

An FDA advisory panel expressed support for a blood test designed to detect early signs of multiple cancers, including some for which no screening alternative exists.Members of the Medical Devices Advisory Committee’s Molecular and Clinical Genetics Panel voted 7 to 2 with one abstention that the benefits of Galleri (Grail Inc.) outweigh the potential risks for adults age 50 years or older,

Aggressive prostate cancer treatment is evolving. Find out how new therapies are changing outcomes and patient care.

The gene is found predominantly in Southern Appalachia and may be one of the most powerful cancer-risk mutations ever found.

Boston 25 Weather Lindsay Clancy Trial(Opens in new window) Zip Trips(Opens in new window) The Local Life(Opens in new window) Share With Us(Opens in new window)

This year's Power 50: The Movement Makers are shaking things up and making things happen. Check out this year's list of powerhouse professionals effecting change in communities across Greater Boston.

Dana-Farber's CEO and chief medical officer spoke with the Business Journal about planning work for the new hospital. Here's how Dana-Farber is planning for the first patients at its $2B hospital.

In this episode of Cancer Questions with Dana-Farber, Mark Pomerantz, MD, discusses the complexities of prostate cancer screening. The American Cancer Society recommends that men over 50 with a 10-year or more life expectancy consider PSA screening and consult their primary care doctor. Screening is especially important for men with a family history of the disease and men of West African ancestry, who should begin screening in their 40s. The goal of screening is to identify aggressive cancers while avoiding unnecessary treatments for low-risk prostate cancers, which are often managed with active monitoring. Want to learn more about prostate cancer risk and prevention? Visit: https://www.dana-farber.org/cancer-care/types/prostate-cancer Watch more episodes of Cancer Questions here: https://www.youtube.com/playlist?list=PLPLXayOtubE2LViqKyqzLOitjINE2JWvT TRANSCRIPT: Welcome to Cancer Questions with Dana-Farber. My name is Mark Pomerantz. I'm a medical oncologist at Dana-Farber. I'm with the general urinary oncology division. Today's question is: should I get screened for prostate cancer? The issue of prostate cancer screening has been controversial for decades. Prostate cancer is the second leading cause of cancer death among men in the United States. At the same time, most prostate cancers are harmless. The American Cancer Society recommends that all men over the age of 50, with a ten-year life expectancy or more, should strongly consider PSA screening and should discuss the prospect of screening with their primary care doctor. There are two groups in particular that should be getting screened: men with a family history of the disease and men of West African ancestry. Screening should begin earlier in their 40s. Prostate cancer is exceedingly common. If we go looking for prostate cancer, we're going to find a lot of prostate cancer. And this has consequences. It could lead to unnecessary treatments that have lifelong side effects. So, our goal has been to identify the dangerous cases while avoiding the prostate cancers that will never cause harm. Most men with low grade, low volume prostate cancer are referred for active monitoring, with blood tests, imaging and biopsies to make sure that they have a prostate cancer that does not deserve aggressive treatment.

Frontline researcher sees a newly approved medication as a "critical first step" toward transformation of care.

Learn what to expect during radioligand therapy infusion for prostate cancer, including safety protocols, side effects, and at-home radiation precautions.

The new landmark drug treats pancreatic cancer in its advanced stages and extends the survival rate of participants in the trial by a median of 13.2 months.

A first-of-a-kind pancreatic cancer drug given approval by the FDA on Wednesday was trialed at Dana-Farber in Boston. It offers a new approach to treating the deadly form of cancer.

The companies have not published the trial data but said in a news release that the experimental treatment extended the time before cancer returned in high-risk patients.

Learn how Dana-Farber-led research helped establish ctDNA testing to guide atezolizumab after surgery for muscle-invasive bladder cancer.

The U.S. Food and Drug Administration has approved iberdomide in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma, making it the first approved cereblon E3 ligase modulator (CELMoD) for this disease.

Newer technologies are helping more cancer patients have children after treatment.

Researchers identify a first-in-kind metabolically activated degrader that hints at a new class of protein-degrading drugs